Loading
Showed for the first time that a hormone-suppressing injection also slows neuroendocrine tumour growth.
PROMID, trial NCT00171873 sponsored by Novartis and the German NET study group and reported in 2009, showed for the first time that a hormone-suppressing somatostatin analogue injection also slows neuroendocrine tumour growth. It randomised 85 patients with treatment-naive metastatic midgut neuroendocrine tumours to octreotide LAR or placebo and met its primary endpoint of time to tumour progression with a large effect, while overall survival did not differ because of crossover and a low event rate. OnCo links it to neuroendocrine tumours and to the somatostatin analogues record, and CLARINET extended the antiproliferative effect to lanreotide across enteropancreatic tumours. Whether starting a somatostatin analogue early changes survival, rather than only delaying progression, remains unproven.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
85 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Time to tumour progressionprimary | Octreotide LAR | 42 | 14.3 months | 0.34 (0.2 to 0.59) | - | link |
| Placebo | 43 | 6 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Somatostatin analogues (octreotide, lanreotide), Small intestinal neuroendocrine tumours, Neuroendocrine tumours.
Shares Somatostatin analogues (octreotide, lanreotide), Small intestinal neuroendocrine tumours, Novartis, Neuroendocrine tumours.
Shares Somatostatin analogues (octreotide, lanreotide), Neuroendocrine tumours.
Shares Somatostatin analogues (octreotide, lanreotide), Novartis.
Shares Somatostatin analogues (octreotide, lanreotide), Small intestinal neuroendocrine tumours, Neuroendocrine tumours.
Shares Somatostatin analogues (octreotide, lanreotide), Small intestinal neuroendocrine tumours.
Shares Small intestinal neuroendocrine tumours, Novartis, Neuroendocrine tumours.
Shares Small intestinal neuroendocrine tumours, Neuroendocrine tumours.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/